Skip to content

Clinical trials

Phase 1 Graft vs Host Disease trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Graft vs Host Disease Phase: Phase 1 Clear all

95 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20021
20033
20043
20061
20073
20088
20091
20102
20112
20122
20133
20145
20156
20163
20175
20184
20193
20207
20215
20222
20232
20244
20251
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed52
Terminated18
Recruiting10
Unknown status6
Not yet recruiting4
Withdrawn4
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Massachusetts General Hospital5
Baylor College of Medicine4
Dana-Farber Cancer Institute4
H. Lee Moffitt Cancer Center and Research Institute3
MedImmune LLC3
National Institute of Allergy and Infectious Diseases (NIAID)3
Northwestern University3
Washington University School of Medicine3
City of Hope Medical Center2
Emory University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Graft vs Host Disease95
Myelodysplastic Syndromes22
Precursor Cell Lymphoblastic Leukemia-Lymphoma17
Leukemia15
Leukemia, Myeloid, Acute14
Lymphoma14
Multiple Myeloma14
Leukemia, Lymphocytic, Chronic, B-Cell13
Lymphoma, Non-Hodgkin12
Neoplasms, Plasma Cell11

Trials

Showing 51 to 75 of 95. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.